HomeProductsBuilding BlocksHeterocyclic ScaffoldsAromatic HeterocyclesTezosentan
Chemical structure of CAS 180384-57-0

Tezosentan

In Stock•Starting at $1076 for 1 mg•Purity ≥ 98.79%
CAS No.180384-57-0
MDL No.N/A
MFC27H27N9O6S
MW605.60
InChI KeyTUYWTLTWNJOZNY-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98.79%$1076In Stock
5 mg98.79%$2676In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.180384-57-0
Product NameTezosentan

Biological Targets

EDNRA·EDNRB

Associated Conditions

pulmonary arterial hypertension·heart failure
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.

Circulation • Vol. 103, Issue 7 • 2001
PMID: 11181472DOI: 10.1161/01.cir.103.7.973

The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function.

Transplantation • Vol. 71, Issue 2 • 2001
PMID: 11213061DOI: 10.1097/00007890-200101270-00007

50th Annual scientific sessions of the American college of cardiology.

Circulation • Vol. 103, Issue 14 • 2001
PMID: 11294821DOI: 10.1161/01.cir.103.14.e9030

Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.

European journal of heart failure • Vol. 3, Issue 3 • 2001
PMID: 11378012DOI: 10.1016/s1388-9842(01)00149-0

Documentation

Similar Products